Chemomab Therapeutics Ltd.

NasdaqCM:CMMB Stock Report

Market Cap: US$16.3m

Chemomab Therapeutics Future Growth

Future criteria checks 0/6

Chemomab Therapeutics's earnings are forecast to decline at 17.5% per annum while its annual revenue is expected to grow at 90.4% per year. EPS is expected to grow by 69% per annum.

Key information

-17.5%

Earnings growth rate

69.01%

EPS growth rate

Biotechs earnings growth25.1%
Revenue growth rate90.4%
Future return on equityn/a
Analyst coverage

Low

Last updated18 May 2026

Recent future growth updates

Recent updates

Analysis Article • Jan 10

Will Chemomab Therapeutics (NASDAQ:CMMB) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Sep 19

Chemomab Therapeutics (NASDAQ:CMMB) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Aug 12

Chemomab Therapeutics - ADR GAAP EPS of -$0.027

Chemomab Therapeutics - ADR press release (NASDAQ:CMMB): Q2 GAAP EPS of -$0.027. Cash, cash equivalents and bank deposits were $51.8 million as of June 30, 2022, compared to $57.5 million at March 31, 2022.
Seeking Alpha • Dec 03

Chemomab Therapeutics: Pioneering Anti-CCL24 MAb For Fibrotic Diseases

Chemomab Therapeutics is advancing a first-in-class anti-CCL24 mAb targeting PSC, SSc, and NASH. Lead candidate CM-101 has orphan drug designation by both the FDA and the EMA in its primary indications of PSC and SSc. The company has a cash runway through mid-2023 and has multiple upcoming catalysts.

Earnings and Revenue Growth Forecasts

NasdaqCM:CMMB - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028N/A-26N/AN/A2
12/31/2027N/A-22N/AN/A2
12/31/2026N/A-12N/AN/A2
3/31/2026N/A-7N/AN/AN/A
12/31/2025N/A-9-11-11N/A
9/30/2025N/A-10N/AN/AN/A
6/30/2025N/A-12-14-14N/A
3/31/2025N/A-13N/AN/AN/A
12/31/2024N/A-14-15-15N/A
9/30/2024N/A-14N/AN/AN/A
6/30/2024N/A-15-16-16N/A
3/31/2024N/A-19N/AN/AN/A
12/31/2023N/A-24-24-24N/A
9/30/2023N/A-29-26-26N/A
6/30/2023N/A-33-26-26N/A
3/31/2023N/A-31-24-24N/A
12/31/2022N/A-28-20-20N/A
9/30/2022N/A-24-18-18N/A
6/30/2022N/A-19-15-15N/A
3/31/2022N/A-16-15-15N/A
12/31/2021N/A-12-13-12N/A
9/30/2021N/A-9-11-11N/A
6/30/2021N/A-8-9-9N/A
3/31/2021N/A-6-5-5N/A
12/31/2020N/A-6-5-5N/A
9/30/2020N/A1110N/A
12/31/2019N/A-7N/A-7N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CMMB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CMMB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CMMB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CMMB is forecast to have no revenue next year.

High Growth Revenue: CMMB is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CMMB's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 08:38
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Chemomab Therapeutics Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason McCarthyMaxim Group
Michael OkunewitchMaxim Group
Jeffrey JonesOppenheimer & Co. Inc.